Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

Unlike healthy, non-transformed cells, the proteostasis network of cancer cells is taxed to produce proteins involved in tumor development. Cancer cells have a higher dependency on molecular chaperones to maintain proteostasis. The chaperonin T-complex protein ring complex (TRiC) contains eight paralogous subunits (CCT1-8), and assists the folding of as many as 10% of cytosolic proteome. TRiC is essential for the progression of some cancers, but the roles of TRiC subunits in osteosarcoma remain to be explored. Here, we show that CCT4/TRiC is significantly correlated in human osteosarcoma, and plays a critical role in osteosarcoma cell survival. We identify a compound anticarin- β that can specifically bind to and inhibit CCT4. Anticarin- β shows higher selectivity in cancer cells than in normal cells. Mechanistically, anticarin- β potently impedes CCT4-mediated STAT3 maturation. Anticarin- β displays remarkable antitumor efficacy in orthotopic and patient-derived xenograft models of osteosarcoma. Collectively, our data uncover a key role of CCT4 in osteosarcoma, and propose a promising treatment strategy for osteosarcoma by disrupting CCT4 and proteostasis. TRiC plays a pivotal role in maintaining proteostasis that is essential to cancer cells. Anticarin- β as CCT4/TRiC inhibitor impedes TRiC-mediated STAT3 maturation on osteosarcoma cells to inducing proteotoxicity and apoptosis.